Novel antibiotics for the management of diabetic foot infections

International Journal of Antimicrobial Agents

Volumn 31, Issue 5, 2008, Pages 411-419

  Omar, Nesrene S ^a   El Nahas, Mamdouh R ^a   Gray, Jim ^b  

^a MANSOURA UNIVERSITY   (Egypt)

^b BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Antibiotics; Bacteria; Diabetic foot infections

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFALEXIN; CEFTOBIPROLE; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERTAPENEM; LINEZOLID; METRONIDAZOLE; MOXIFLOXACIN; ORITAVANCIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULTAMICILLIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL PAIN; ANAEROBE; CLINICAL TRIAL; DIABETIC FOOT; DIARRHEA; DRUG EFFICACY; FEVER; FOOT INFECTION; GRAM NEGATIVE BACTERIUM; HEADACHE; HUMAN; MICROBIOLOGY; MYOPATHY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTI-BACTERIAL AGENTS; DIABETIC FOOT; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 41949136659     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.10.016     Document Type: Short Survey

References (86)

1. Lavery L.A., Armstrong D.G., Wunderlich R.P., Mohler M.J., Wendel C.S., and Lipsky B.A. Risk factors for foot infections in individuals with diabetes. Diabetes Care 29 (2006) 1288-1293
2. Armstrong D.G., and Lipsky B.A. Diabetic foot infections: stepwise medical and surgical management. Int Wound J 1 (2004) 123-132
3. Pecoraro R.E. The non-healing diabetic ulcer-a major cause for limb loss. Prog Clin Biol Res 365 (1991) 27-43
4. Senneville E. Antimicrobial interventions for the management of diabetic foot infections. Expert Opin Pharmacother 6 (2005) 263-273
5. Lee S.Y., Kuti J.L., and Nicolau D.P. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt) 6 (2005) 283-295
6. Padmanabhan R.A., Larosa S.P., and Tomecki K.J. What's new in antibiotics?. Dermatol Clin 23 (2005) 301-312
7. Lipsky B.A., Berendt A.R., Deery H.G., Embil J.M., Joseph W.S., Karchmer A.W., et al., Infectious Diseases Society of America. Diagnosis and treatment of diabetic foot infections. Plast Reconstr Surg 117 Suppl. (2006) 212S-238S
8. O'Meara S., Nelson E.A., Golder S., Dalton J.E., Craig D., Iglesias C., and DASIDU Steering Group. Systematic review of methods to diagnose infection in foot ulcers in diabetes. Diabet Med 23 (2006) 341-347
9. Loan C.A., Legout L., Assal M., Rohner P., Hoffmeyer P., and Bernard L. Severe Streptococcus agalactiae infection of the diabetic foot. A deleterious role of Streptococcus agalactiae?. Presse Med 34 (2005) 491-494 [in French]
10. Abdulrazak A., Bitar Z.I., Al-Shamali A.A., and Mobasher L.A. Bacteriological study of diabetic foot infections. J Diabetes Complications 19 (2005) 138-141
11. Chincholikar D.A., and Pal R.B. Study of fungal and bacterial infections of the diabetic foot. Indian J Pathol Microbiol 45 (2002) 15-22
12. El-Tahawy A.T. Bacteriology of diabetic foot. Saudi Med J 21 (2000) 344-347
13. Gadepalli R., Dhawan B., Sreenivas V., Kapil A., Ammini A.C., and Chaudhry R. A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. Diabetes Care 29 (2006) 1727-1732
14. Viswanathan V., Jasmine J.J., Snehalathe C., and Ramachandran A. Prevalence of pathogens in diabetic foot infection in South Indian type 2 diabetic patients. J Assoc Physicians India 50 (2002) 1013-1016
15. Yoga R., Khairul A., Sunita K., and Suresh C. Bacteriology of diabetic foot lesions. Med J Malaysia 61 Suppl. A (2006) 14-16
16. Unachukwu C.N., Obunge O.K., and Odia O.J. The bacteriology of diabetic foot ulcers in Port Harcourt, Nigeria. Niger J Med 14 (2005) 173-176
17. Kengne A.P., Choukem S.P., Dehayem Y.M., Simo N.L., Fezeu L.L., and Mbanya J.C. Diabetic foot ulcers in Cameroon: can microflora prevalence inform probabilistic antibiotic treatment?. J Wound Care 15 (2006) 363-366
18. Dang C.N., Prasad Y.D., Boulton A.J., and Jude E.B. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 20 (2003) 159-161
19. Kessler L., Piemont Y., Ortega F., Lesens O., Boeri C., Averous C., et al. Comparison of microbiological results of needle puncture vs. superficial swab in infected diabetic foot ulcer with osteomyelitis. Diabet Med 23 (2006) 99-102
20. Hartemann-Heurtier A., Robert J., Jacqueminet S., Ha Van G., Golmard J.L., Jarlier V., et al. Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. Diabet Med 21 (2004) 710-715
21. Kandemir O., Akbay E., Sahin E., Milcan A., and Gen R. Risk factors for infection of the diabetic foot with multi-antibiotic resistant microorganisms. J Infect 54 (2007) 439-445
22. Goldstein E.J., Citron D.M., and Nesbit C.A. Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Diabetes Care 19 (1996) 638-641
23. Tentoluris N., Jude E.B., Smirnof I., Knowles E.A., and Boulton A.J. Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med 16 (1999) 767-771
24. Tarshoby M., State O., Sawish H., Omar N., and El-Nahas M. Prevalence and antibiotic susceptibility of MRSA in diabetic foot ulcer in Egyptian diabetes foot clinic. 5th International Symposium on the Diabetic Foot. Noordwijkerhout, The Netherlands (9-12 May 2007)
25. Tentolouris N., Petrikkos G., Vallianou N., Zachos C., Daikos G.L., Tsapogas P., et al. Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin Microbiol Infect 12 (2006) 186-189
26. Moran G.J., Krishnadasan A., Gorwitz R.J., Fosheim G.E., McDougal L.K., Carey R.B., et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355 (2006) 666-674
27. Shankar E.M., Mohan V., Premalatha G., Srinivasan R.S., and Usha A.R. Bacterial etiology of diabetic foot infections in South India. Eur J Intern Med 16 (2005) 567-570
28. Brem H., Sheehan P., Rosenberg H.J., Schneider J.S., and Boulton A.J. Evidence-based protocol for diabetic foot ulcers. Plast Reconstr Surg 117 Suppl. (2006) 193S-209S
29. Edmonds M. Diabetic foot ulcers: practical treatment recommendations. Drugs 66 (2006) 913-929
30. Rathur H.M., and Boulton A.J. The diabetic foot. Clin Dermatol 25 (2007) 109-120
31. Holstein P.E., and Sørensen S. Limb salvage experience in a multidisciplinary diabetic foot unit. Diabetes Care 22 Suppl. 2 (1999) B97-B103
32. Todd W.F., Armstrong D.G., and Liswood P.J. Evaluation and treatment of the infected foot in a community teaching hospital. J Am Podiatr Med Assoc 86 (1996) 421-426
33. Nelson E.A., O'Meara S., Golder S., Dalton J., Craig D., Iglesias C., and DASIDU Steering Group. Systematic review of antimicrobial treatments for diabetic foot ulcers. Diabet Med 23 (2006) 348-359
34. Jeffcoate W.J., Chipchase S.Y., Ince P., and Game F.L. Assessing the outcome of the management of diabetic foot ulcers using ulcer-related and person-related measures. Diabetes Care 29 (2006) 2784-2787
35. Oyibo S.O., Jude E.B., Tarawneh I., Nguyen H.C., Harkless L.B., and Boulton A.J. A comparison of two diabetic foot ulcer classification systems: the Wager and the University of Texas wound classification systems. Diabetes Care 24 (2001) 84-88
36. Gul A., Basit A., Ali S.M., Ahmadani M.Y., and Miyan Z. Role of wound classification in predicting the outcome of diabetic foot ulcer. J Pak Med Assoc 56 (2006) 444-447
37. Lipsky B.A., Sheehan P., Armstrong D.G., Tice A.D., Pollis A.B., and Abramson M.A. Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial. Int Wound J 4 (2007) 30-38
38. Société de Pathologie Infectieuse de Langue Française. Management of diabetic foot infections. Med Mal Infect 2007; 37:14-25.
39. Rao N., and Lipsky B.A. Optimising antimicrobial therapy in diabetic foot infections. Drugs 67 (2007) 195-214
40. Stein G.E., Schooley S., Peloquin C.A., Missavage A., and Havlichek D.H. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother 60 (2007) 819-823
41. Lipsky B.A., Itani K., Norden C., and Linezolid Diabetic Foot Infections Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 38 (2004) 17-24
42. Weigelt J., Itani K., Stevens D., Lau W., Dryden M., Knirsch C., and Linezolid CSSTI Study Group. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49 (2005) 2260-2266
43. McKinnon P.S., Sorensen S.V., Liu L.Z., and Itani K.M. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother 40 (2006) 1017-1023
44. McCollum M., Sorensen S.V., and Liu L.Z. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients. Clin Ther 29 (2007) 469-477
45. Patanwala A.E., Erstad B.L., and Nix D.E. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections. Curr Med Res Opin 23 (2007) 185-193
46. Ross J.E., Fritsche T.R., Sader H.S., and Jones R.N. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study. Int J Antimicrob Agents 29 (2007) 295-301
47. Rybak M.J. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Clin Microbiol Infect 12 Suppl. 1 (2006) 24-32
48. Eisenstein B.I. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin Investig Drugs 13 (2004) 1159-1169
49. Lipsky B.A., and Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 55 (2005) 240-245
50. Benvenuti M., Benziger D.P., Yankelev S., and Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram body weight once daily in healthy volunteers. Antimicrob Agents Chemother 50 (2006) 3245-3249
51. Veligandla S.R., Louie K.R., Malesker M.A., and Smith P.W. Muscle pain associated with daptomycin. Ann Pharmacother 38 (2004) 1860-1862
52. Garau J. Management of cSSTIs: the role of daptomycin. Curr Med Res Opin 22 (2006) 2079-2087
53. Pfaller M.A., Sader H.S., and Jones R.N. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Diagn Microbiol Infect Dis 57 (2007) 459-465
54. Boucher H.W., and Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 45 (2007) 601-608
55. Gurk-Turner C. Quinupristin/dalfopristin: the first available macrolide-lincosamide-streptogramin antibiotic. Proc (Bayl Univ Med Cent) 13 (2000) 83-86
56. Raad I., Hachem R., and Hanna H. Relationship between myalgias/arthralgias occurring in patients receiving quinupristin/dalfopristin and biliary dysfunction. J Antimicrob Chemother 53 (2004) 1105-1108
57. Carver P.L., Whang E., VandenBussche H.L., Kauffmann C.A., and Malani P.N. Risk factors for arthralgias or myalgias associated with quinupristin-dalfopristin therapy. Pharmacotherapy 23 (2003) 159-164
58. Decousser J.W., Bourgeois-Nicolaos N., and Doucet-Populaire F. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria. Expert Rev Anti Infect Ther 5 (2007) 557-571
59. Goldstein E.J.C., Citron D.M., Warren Y.A., Tyrrell K.L., Marriam C.V., and Fernandez H.T. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infections. Antimicrob Agents Chemother 50 (2006) 2875-2879
60. Scheinfeld N. Dalbavancin: a review for dermatologists. Dermatol Online J 12 (2006) 6
61. Pope S.D., and Roecker A.M. Dalbavancin: a novel lipoglycopeptide antibacterial. Pharmacotherapy 26 (2006) 908-918
62. Jauregui L.E., Babazadeh S., Seltzer E., Goldberg L., Krievins D., Frederick M., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 41 (2005) 1407-1415
63. Seltzer E., Dorr M.B., Goldstein B.P., Perry M., Dowell J.A., Henkel T., and Dalbavancin Skin and Soft-Tissue Infection Study Group. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 37 (2003) 1298-1303
64. Laohavaleeson S., Kuti J.L., and Nicolau D.P. Telavancin: a novel lipoglycopeptide for serious Gram-positive infections. Expert Opin Investig Drugs 16 (2007) 347-357
65. Kanafani Z.A. Telavancin: a new lipoglycopeptide with multiple mechanisms of action. Expert Rev Anti Infect Ther 4 (2006) 743-749
66. Jansen W.T., Verel A., Verhoef J., and Milatovic D. In vitro activity of telavancin against Gram-positive clinical isolates recently obtained in Europe. Antimicrob Agents Chemother 51 (2007) 3420-3424
67. Stryjewski M.E., Chu V.H., O'Riordan W.D., Warren B.L., Dunbar L.M., Young D.M., et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 50 (2006) 862-867
68. Stryjewski M.E., O'Riordan W.D., Lau W.K., Pien F.D., Dunbar L.M., Vallee M., et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. Clin Infect Dis 40 (2005) 1601-1607
69. Hegde S.S., Reyes N., Wiens T., Vanasse N., Skinner R., McCullough J., et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob Agents Chemother 48 (2004) 3043-3050
70. Mercier R.C., and Hrebockova L. Oritavancin: a new avenue for resistant Gram-positive bacteria. Expert Rev Anti Infect Ther 3 (2005) 325-332
71. Doan T.L., Fung H.B., Mehta D., and Riska P.F. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther 28 (2006) 1079-1106
72. Meagher A.K., Ambrose P.G., Grasela T.H., and Ellis-Grosse E.J. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 41 Suppl. 5 (2005) C333-C340
73. Amyes G.S. Enterococci and streptococci. Int J Antimicrob Agents 29 Suppl. 3 (2007) S43-S52
74. Navon-Nenezia S., Leavitt A., and Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 59 (2007) 772-774
75. Reid G.E., Grim S.A., Aldeza C.A., Janda W.M., and Clark N.M. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 27 (2007) 1198-1201
76. Grolman D.C. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections. Int J Infect Dis 11 Suppl. 1 (2007) S7-S15
77. Livermore D. Can beta-lactams be re-engineered to beat MRSA?. Clin Microbiol Infect 12 Suppl. 2 (2006) 11-16
78. Bush K., Heep M., Macielag M.J., and Noel G.J. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs 16 (2007) 419-421
79. Noel G.J. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic. Clin Microbiol Infect 13 Suppl. 2 (2007) 25-29
80. Goldstein E.J.C., Citron D.M., Merriam C.V., Warren Y.A., Tyrrel K.L., and Fernandez H.T. In-vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob Agents Chemother 50 (2006) 3959-3962
81. Garcia-Rodrigeuz J.A., and Gómez Garcia A.C. The microbiology of moxifloxacin. Drugs Today (Barc) 36 (2007) 215-227
82. MacGowan A.P. Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. Expert Opin Investig Drugs 8 (1999) 181-199
83. Lipsky B.A., Giordano P., Choudhri S., and Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother 60 (2007) 370-376
84. Pelak B.A., Bartizal K., Woods G.L., Gesser R.M., and Motyl M. Comparative in vitro activities of ertapenem against aerobic and facultative bacterial pathogens from patients with complicated skin and skin structure infections. Diagn Microbiol Infect Dis 43 (2002) 129-133
85. Solomkin J., Teppler H., Graham D.R., Gesser R.M., Meibohm A.R., Roy S., et al. Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam. J Antimicrob Chemother 53 Suppl. 2 (2004) ii51-ii57
86. Lipsky B.A., Armstrong D.G., Citron D.M., Tice A.D., Morgenstern D.E., and Abramson M.A. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomized, controlled, double-blinded, multicentre trial. Lancet 366 (2005) 1695-1703